Mitotic kinases, including AURKA, are key signaling components of genotoxic response pathways.32 Previous studies have documented aberrant expression of AURKA in various carcinomas and hematological malignancies.7, 33 In addition, our earlier data has also suggested that AURKA was highly expressed in epirubicin resistance breast tumor initiating cells and contributed to the maintenance of stemness and drug resistance in breast cancer.34 Given the essential roles of AURKA overexpression in cancer progression, targeting AURKA offers an attractive approach for cancer therapy. This evidence concerns the gene AURKA and breast carcinoma.